[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].
Mitsuya
H
H
National Cancer Institute, National Institutes of Health.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D016049:Didanosine / Q000009:adverse effects / Q000494:pharmacology; D017320:HIV Protease Inhibitors; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000201:enzymology; D006801:Humans; D018894:Reverse Transcriptase Inhibitors; D013941:Thymine / Q000031:analogs & derivatives / Q000494:pharmacology; D016047:Zalcitabine / Q000494:pharmacology; D015215:Zidovudine / Q000009:adverse effects / Q000494:pharmacology
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; C061818:1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine; D015215:Zidovudine; D016047:Zalcitabine; D054303:HIV Reverse Transcriptase; D016049:Didanosine; D013941:Thymine